Is MEDP a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Biotech-focused organic model, with revenue (ttm) at ~$2.78B; Q2 2026 ~$707M, up ~17% YoY. The bear case rests on the biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists. Analysts covering it are spread from $370.00 to $700.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $370.00, -40.2% from the $618.47 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Biotech-focused organic model. Medpace concentrates on small and mid-cap biotech sponsors and complex trials rather than scaling through acquisitions like larger peers. The most optimistic analyst target on MEDP is $700.00, +13.2% from the $618.47 price. That figure is only reachable if this thesis works close to its best case.

The biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists. Analyst estimates point to revenue growth slowing sharply by the fourth quarter of 2026 (about $721 million expected, versus roughly $708 million a year earlier). Medpace's heavy exposure to small and mid-cap biotech makes it sensitive to swings in biotech funding and sentiment. A market-wide fear that AI will reduce the labor and pricing of clinical trials has compressed CRO valuations, and management itself expects AI spending to exceed savings through 2026-2027. Trial cancellations, delays, and sponsor consolidation can create lumpy results, and competition from far larger CROs (IQVIA, ICON, and others) is intense. The stock has been volatile, falling to about $373 and recovering to the low $600s within a year, and at about 32 times forward earnings it now trades above the analyst mean target of about $596 (October 2026). Insiders sold shares in late September 2026, including one sale worth about $30 million. The most pessimistic published target is $370.00, -40.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Medpace Holdings is a full-service, global clinical contract research organization that designs and runs Phase I through Phase IV clinical trials for biotechnology, pharmaceutical,

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Biotech-focused organic model) stalling in the reported numbers rather than in the narrative, the risk above (the biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Medpace is a clinical contract research organization (CRO) that plans and runs clinical trials (Phase I through Phase IV) for biotech, pharmaceutical, and medical device companies. Sponsors outsource trial design, patient enrollment, monitoring, and regulatory work to Medpace.

Yes. Medpace is consistently profitable with high margins. It reported roughly $707 million of revenue and about $4.25 of diluted EPS in Q2 2026 (after about $4.28 in Q1), and trailing net income of about $492 million as of October 2026. It generates strong operating cash flow, about $753 million over the trailing twelve months, with an operating margin around 21 percent.

Despite beating earnings, shares fell sharply after Q1 2026 because net book-to-bill dipped below 1.0 and cancellations reached a multi-quarter high. Broader worries that AI could disrupt CRO economics also pressured the whole sector. The drop did not last: by October 16, 2026 the stock had climbed back to about $621, up roughly 9% for the year.